{"protocolSection": {"identificationModule": {"nctId": "NCT01544348", "orgStudyIdInfo": {"id": "CD-RI-MEDI4212-1085"}, "organization": {"fullName": "MedImmune LLC", "class": "INDUSTRY"}, "briefTitle": "A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL", "officialTitle": "A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE >= 30 IU/mL"}, "statusModule": {"statusVerifiedDate": "2014-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-01"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-01-31", "studyFirstSubmitQcDate": "2012-03-02", "studyFirstPostDateStruct": {"date": "2012-03-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-12-18", "resultsFirstSubmitQcDate": "2014-12-18", "resultsFirstPostDateStruct": {"date": "2014-12-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-12-18", "lastUpdatePostDateStruct": {"date": "2014-12-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "MedImmune LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Phase 1 study to evaluate the safety of MEDI4212.", "detailedDescription": "A Phase 1, randomized, placebo-controlled, dose-escalation study to evaluate the safety and tolerability of ascending single subcutaneous and intravenous doses of MEDI4212 in subjects with immunoglobulin E (IgE) greater than or equal to (\\>=) 30 international units per milliliters (IU/mL)."}, "conditionsModule": {"conditions": ["Allergic Asthma", "Atopic Dermatitis", "Allergic Rhinitis", "Healthy Volunteers"], "keywords": ["Allergic", "Atopic Dermatitis", "MEDI4212"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 295, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.", "interventionNames": ["Other: Placebo"]}, {"label": "Omalizumab", "type": "ACTIVE_COMPARATOR", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.", "interventionNames": ["Biological: Omalizumab"]}, {"label": "MEDI4212 5 mg Subcutaneous", "type": "EXPERIMENTAL", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.", "interventionNames": ["Biological: MEDI4212 5 mg Subcutaneous"]}, {"label": "MEDI4212 15 mg Subcutaneous", "type": "EXPERIMENTAL", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.", "interventionNames": ["Biological: MEDI4212 15 mg Subcutaneous"]}, {"label": "MEDI4212 60 mg Subcutaneous", "type": "EXPERIMENTAL", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.", "interventionNames": ["Biological: MEDI4212 60 mg Subcutaneous"]}, {"label": "MEDI4212 150 mg Subcutaneous", "type": "EXPERIMENTAL", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.", "interventionNames": ["Biological: MEDI4212 150 mg Subcutaneous"]}, {"label": "MEDI4212 300 mg Subcutaneous", "type": "EXPERIMENTAL", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.", "interventionNames": ["Biological: MEDI4212 300 mg Subcutaneous"]}, {"label": "MEDI4212 300 mg Intravenous", "type": "EXPERIMENTAL", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.", "interventionNames": ["Biological: MEDI4212 300 mg Intravenous"]}], "interventions": [{"type": "OTHER", "name": "Placebo", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.", "armGroupLabels": ["Placebo"]}, {"type": "BIOLOGICAL", "name": "Omalizumab", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.", "armGroupLabels": ["Omalizumab"], "otherNames": ["Xolair"]}, {"type": "BIOLOGICAL", "name": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.", "armGroupLabels": ["MEDI4212 5 mg Subcutaneous"]}, {"type": "BIOLOGICAL", "name": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.", "armGroupLabels": ["MEDI4212 15 mg Subcutaneous"]}, {"type": "BIOLOGICAL", "name": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.", "armGroupLabels": ["MEDI4212 60 mg Subcutaneous"]}, {"type": "BIOLOGICAL", "name": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.", "armGroupLabels": ["MEDI4212 150 mg Subcutaneous"]}, {"type": "BIOLOGICAL", "name": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.", "armGroupLabels": ["MEDI4212 300 mg Subcutaneous"]}, {"type": "BIOLOGICAL", "name": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.", "armGroupLabels": ["MEDI4212 300 mg Intravenous"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)", "description": "An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to Day 85 that were absent before treatment or that worsened relative to pre-treatment state.", "timeFrame": "Day 1 to 85"}], "secondaryOutcomes": [{"measure": "Observed Serum Concentration", "description": "Serum concentration of omalizumab and MEDI4212 were measured for participants who received omalizumab and MEDI4212, respectively.", "timeFrame": "Pre-dose and post-dose on Day 1; Day 2, 3, 5, 8, 15, 22, 29, 43, 57 and 85"}, {"measure": "Number of Participants Exhibiting Anti-Drug Antibodies for MEDI4212 at Any Visit", "description": "Anti-drug antibodies for MEDI4212 were analyzed for participants who received placebo or MEDI4212 as per planned analysis.", "timeFrame": "Days 1 (pre-dose), 15, 43, and 85"}, {"measure": "Free Immunoglobulin E (IgE) Serum Concentration", "timeFrame": "Day -28 (Screening), -1, 1 (pre-dose), 2, 3, 5, 8, 15, 22, 29, 43, 57, and 85 for all groups; 2 hours post-dose on Day 1 for MEDI4212 300 mg Intravenous group only"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 through 60 years\n* Written informed consent and any locally required authorization\n* Body weight 45-150 kilogram (kg) for Cohorts 1-3, 4b, and 5-9. Body weight 45-90 kg for Cohort 4a\n* Females must have been surgically sterilized or postmenopausal\n* Non-sterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through Day 85; Both partners to use contraception\n* Sterilized males must be at least 1-year post vasectomy or use a highly effective contraceptive method\n* Healthy Japanese population as determined by a responsible physician\n* Current diagnosis of allergic rhinitis, allergic asthma, or atopic dermatitis (cohorts 1-6) with a diagnostic immunoglobulin E (IgE) of 30 international units per milliliter (IU/mL) at Screening. Diagnostic IgE levels are further restricted for subjects enrolling into each cohort, with the following levels required at Screening: Cohorts 1 and 2: 30-700 IU/mL; Cohort 3: 30-700 IU/mL (4 subjects), greater than (\\>) 700-1,200 IU/mL (4 subjects), and \\>1,200 IU/mL (4 subjects); Cohort 4a: 30-500 IU/mL; Cohort 4b: \\>700 IU/mL; Cohorts 5 and 6: 30-700 IU/mL (4 subjects per cohort) and \\>700 IU/mL (6 subjects per cohort) or Japanese Cohorts 7-9: greater than or equal to (\\>=) 30 IU/mL\n* Nonsmoker for \\>=6 months\n* Obsolete criteria as no longer require Positive in vitro IgE fluorescence enzyme immunoassay (FEIA) response\n* A forced expiration volume in one second (FEV1) \\>= 80 percent (%) predicted in subjects with asthma. Non-asthmatic subjects with FEV1 \\>=80% predicted, or with FEV1 less than (\\<) 80% predicted but who, in the opinion of the investigator, do not have lung disease\n* Ability and willingness to complete the follow-up period through Day 85 as required by the protocol.\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results\n* Concurrent enrollment in another clinical study\n* Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals\n* Exposure to an anti-IgE monoclonal antibodies (MAb) within 12 months prior to Screening\n* Positive drug screen at Screening or Day -1. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, and benzodiazepines\n* History of regular alcohol abuse within 12 months prior to Screening\n* History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation\n* Subjects with abnormal liver function test values (aspartate transaminase \\[AST\\] and alanine transaminase \\[ALT\\]) at Screening as defined as follows: a) Liver function test values \\>= 1.5 times upper limit of normal (ULN)\n* Unwillingness or inability to follow the procedures outlined in the protocol\n* Positive test or history of hepatitis B or positive hepatitis C\n* Positive test or history of human immunodeficiency virus (HIV) or subject is known to be HIV seropositive\n* History of cancer, with the exception of basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success\n* Women who are pregnant, breastfeeding, or lactating\n* Plans to donate blood during the study period\n* Hyper-IgE syndrome or bronchopulmonary aspergillosis\n* Prior history of Immune Complex Disease or type 3 hypersensitivity reactions to MAb administration\n* Known history of prior infusion reaction to MAb administration\n* History of untreated parasitic/helminthic infection within 6 months prior to Screening\n* Uses any of the following medications: a) Oral corticosteroids b) Medium to high dose Immunocorticosteroids (ICS)/ long-acting beta agonists (LABA) c) Immunosuppressives d) Beta blockers\n* If receiving allergy immunotherapy, must be on stable dose for 3 months. Must not receive allergy immunotherapy within 7 days of investigational product administration.", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Cypress", "state": "California", "country": "United States", "geoPoint": {"lat": 33.81696, "lon": -118.03729}}, {"facility": "Research Site", "city": "Glendale", "state": "California", "country": "United States", "geoPoint": {"lat": 34.14251, "lon": -118.25508}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"references": [{"pmid": "26843086", "type": "DERIVED", "citation": "Sheldon E, Schwickart M, Li J, Kim K, Crouch S, Parveen S, Kell C, Birrell C. Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study. Adv Ther. 2016 Feb;33(2):225-51. doi: 10.1007/s12325-016-0287-8. Epub 2016 Feb 3."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 295 participants were screened, out of which 209 were screen failures and 86 were randomized.", "groups": [{"id": "FG000", "title": "Placebo", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1."}, {"id": "FG001", "title": "Omalizumab", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1."}, {"id": "FG002", "title": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1."}, {"id": "FG003", "title": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1."}, {"id": "FG004", "title": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1."}, {"id": "FG005", "title": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1."}, {"id": "FG006", "title": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1."}, {"id": "FG007", "title": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "19"}, {"groupId": "FG006", "numSubjects": "14"}, {"groupId": "FG007", "numSubjects": "8"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "15"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "14"}, {"groupId": "FG007", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "15"}, {"groupId": "FG005", "numSubjects": "16"}, {"groupId": "FG006", "numSubjects": "12"}, {"groupId": "FG007", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "3"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety population included all participants who received any amount of investigational product and had safety data available.", "groups": [{"id": "BG000", "title": "Placebo", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1."}, {"id": "BG001", "title": "Omalizumab", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1."}, {"id": "BG002", "title": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1."}, {"id": "BG003", "title": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1."}, {"id": "BG004", "title": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1."}, {"id": "BG005", "title": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1."}, {"id": "BG006", "title": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1."}, {"id": "BG007", "title": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1."}, {"id": "BG008", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "18"}, {"groupId": "BG006", "value": "14"}, {"groupId": "BG007", "value": "8"}, {"groupId": "BG008", "value": "84"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.6", "spread": "12.6"}, {"groupId": "BG001", "value": "39.3", "spread": "9.2"}, {"groupId": "BG002", "value": "44.7", "spread": "3.2"}, {"groupId": "BG003", "value": "40.3", "spread": "9.6"}, {"groupId": "BG004", "value": "38.7", "spread": "12.5"}, {"groupId": "BG005", "value": "40.3", "spread": "11.1"}, {"groupId": "BG006", "value": "35.9", "spread": "13.1"}, {"groupId": "BG007", "value": "38.0", "spread": "8.6"}, {"groupId": "BG008", "value": "39.0", "spread": "11.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "4"}, {"groupId": "BG006", "value": "2"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "22"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "11"}, {"groupId": "BG005", "value": "14"}, {"groupId": "BG006", "value": "12"}, {"groupId": "BG007", "value": "8"}, {"groupId": "BG008", "value": "62"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)", "description": "An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to Day 85 that were absent before treatment or that worsened relative to pre-treatment state.", "populationDescription": "Safety population included all participants who received any amount of investigational product and had safety data available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 to 85", "groups": [{"id": "OG000", "title": "Placebo", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1."}, {"id": "OG001", "title": "Omalizumab", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1."}, {"id": "OG002", "title": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1."}, {"id": "OG003", "title": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1."}, {"id": "OG004", "title": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1."}, {"id": "OG005", "title": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1."}, {"id": "OG006", "title": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1."}, {"id": "OG007", "title": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "3"}, {"groupId": "OG004", "value": "15"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "14"}, {"groupId": "OG007", "value": "8"}]}], "classes": [{"title": "TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "4"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "7"}, {"groupId": "OG007", "value": "6"}]}]}, {"title": "TESAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Observed Serum Concentration", "description": "Serum concentration of omalizumab and MEDI4212 were measured for participants who received omalizumab and MEDI4212, respectively.", "populationDescription": "Pharmacokinetic (PK) population included all participants who received any investigational product and had a sufficient number of serum concentration measurements for computing PK parameters. Here 'n' signifies participants evaluable for this outcome measure at specified time point, for each group respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nanogram per milliliter (ng/mL)", "timeFrame": "Pre-dose and post-dose on Day 1; Day 2, 3, 5, 8, 15, 22, 29, 43, 57 and 85", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1."}, {"id": "OG001", "title": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1."}, {"id": "OG002", "title": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1."}, {"id": "OG003", "title": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1."}, {"id": "OG004", "title": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1."}, {"id": "OG005", "title": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1."}, {"id": "OG006", "title": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "14"}, {"groupId": "OG006", "value": "8"}]}], "classes": [{"title": "Day 1 (predose) (n=0,1,0,0,2,1,1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG001", "value": "96.76", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG004", "value": "254.71", "spread": "134.58"}, {"groupId": "OG005", "value": "91.69", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG006", "value": "158.32", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}]}]}, {"title": "Day 1 (postdose) (n=0,0,0,0,0,0,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG004", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG005", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG006", "value": "110693", "spread": "26060.2"}]}]}, {"title": "Day 2 (n=5,1,1,12,17,13,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8941.12", "spread": "6361.95"}, {"groupId": "OG001", "value": "100.36", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG002", "value": "292.76", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG003", "value": "3146.54", "spread": "3820.61"}, {"groupId": "OG004", "value": "6108.21", "spread": "3401.45"}, {"groupId": "OG005", "value": "14971.9", "spread": "9608.63"}, {"groupId": "OG006", "value": "88457.0", "spread": "23398.4"}]}]}, {"title": "Day 3 (n=5,1,1,12,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13912.4", "spread": "7546.50"}, {"groupId": "OG001", "value": "110.12", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG002", "value": "312.73", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG003", "value": "3131.79", "spread": "2513.43"}, {"groupId": "OG004", "value": "7969.07", "spread": "4004.75"}, {"groupId": "OG005", "value": "14771", "spread": "8692.16"}, {"groupId": "OG006", "value": "69776.5", "spread": "37738.7"}]}]}, {"title": "Day 5 (n=5,1,1,11,16,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "17016.3", "spread": "6806.15"}, {"groupId": "OG001", "value": "116.44", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG002", "value": "284.28", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG003", "value": "3336.31", "spread": "2759.69"}, {"groupId": "OG004", "value": "7227.93", "spread": "3210.9"}, {"groupId": "OG005", "value": "15183.4", "spread": "8522.98"}, {"groupId": "OG006", "value": "34359.5", "spread": "6817.40"}]}]}, {"title": "Day 8 (n=5,0,1,9,16,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "16467.4", "spread": "5374.97"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG002", "value": "190.38", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG003", "value": "2368.21", "spread": "1364.28"}, {"groupId": "OG004", "value": "7144.03", "spread": "5078.61"}, {"groupId": "OG005", "value": "12611.1", "spread": "8382.56"}, {"groupId": "OG006", "value": "39290.2", "spread": "32657.3"}]}]}, {"title": "Day 15 (n=5,0,0,7,14,13,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "15099.6", "spread": "5470.44"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "1134.39", "spread": "259.41"}, {"groupId": "OG004", "value": "4514.83", "spread": "2864.46"}, {"groupId": "OG005", "value": "8824.94", "spread": "6744.55"}, {"groupId": "OG006", "value": "11391.2", "spread": "3673.21"}]}]}, {"title": "Day 22 (n=5,0,0,6,12,10,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12780.2", "spread": "4657.23"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "521.3", "spread": "96.73"}, {"groupId": "OG004", "value": "3401", "spread": "2140.78"}, {"groupId": "OG005", "value": "7454.01", "spread": "4682.86"}, {"groupId": "OG006", "value": "4644.04", "spread": "2571.96"}]}]}, {"title": "Day 29 (n=5,0,0,4,11,8,7)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9466.26", "spread": "4040.07"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "212.22", "spread": "82.96"}, {"groupId": "OG004", "value": "2176.59", "spread": "1390.94"}, {"groupId": "OG005", "value": "2688.85", "spread": "2191.8"}, {"groupId": "OG006", "value": "2045.55", "spread": "1814.12"}]}]}, {"title": "Day 43 (n=5,2,0,0,5,5,3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5195.21", "spread": "2263.08"}, {"groupId": "OG001", "value": "121.39", "spread": "8.11"}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG004", "value": "1544.4", "spread": "2068.43"}, {"groupId": "OG005", "value": "1188.63", "spread": "949.33"}, {"groupId": "OG006", "value": "1669.74", "spread": "739.22"}]}]}, {"title": "Day 57 (n=5,2,0,0,4,4,3)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2367.85", "spread": "984.70"}, {"groupId": "OG001", "value": "122.00", "spread": "0.35"}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG004", "value": "290.44", "spread": "228.81"}, {"groupId": "OG005", "value": "485.18", "spread": "249.73"}, {"groupId": "OG006", "value": "150.90", "spread": "87.96"}]}]}, {"title": "Day 85 (n=5,2,0,1, 3,1,1)", "categories": [{"measurements": [{"groupId": "OG000", "value": "829.55", "spread": "434.33"}, {"groupId": "OG001", "value": "104.07", "spread": "2.48"}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "98.62", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG004", "value": "202.54", "spread": "107.75"}, {"groupId": "OG005", "value": "84.03", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}, {"groupId": "OG006", "value": "176.87", "spread": "NA", "comment": "Standard deviation was not estimable because only 1 participant was evaluable in this reporting group."}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Exhibiting Anti-Drug Antibodies for MEDI4212 at Any Visit", "description": "Anti-drug antibodies for MEDI4212 were analyzed for participants who received placebo or MEDI4212 as per planned analysis.", "populationDescription": "Immunogenicity population included all participants who received any investigational product and had at least one valid immunogenicity test result.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Days 1 (pre-dose), 15, 43, and 85", "groups": [{"id": "OG000", "title": "Placebo", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1."}, {"id": "OG001", "title": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1."}, {"id": "OG002", "title": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1."}, {"id": "OG003", "title": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1."}, {"id": "OG004", "title": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1."}, {"id": "OG005", "title": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1."}, {"id": "OG006", "title": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "14"}, {"groupId": "OG006", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Free Immunoglobulin E (IgE) Serum Concentration", "populationDescription": "Safety population included all participants who received any amount of investigational product and had safety data available. 'n' signifies those participants who evaluable for this outcome measure at specified time point for each group, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day -28 (Screening), -1, 1 (pre-dose), 2, 3, 5, 8, 15, 22, 29, 43, 57, and 85 for all groups; 2 hours post-dose on Day 1 for MEDI4212 300 mg Intravenous group only", "groups": [{"id": "OG000", "title": "Placebo", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1."}, {"id": "OG001", "title": "Omalizumab", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1."}, {"id": "OG002", "title": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1."}, {"id": "OG003", "title": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1."}, {"id": "OG004", "title": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1."}, {"id": "OG005", "title": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1."}, {"id": "OG006", "title": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1."}, {"id": "OG007", "title": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "3"}, {"groupId": "OG004", "value": "15"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "14"}, {"groupId": "OG007", "value": "8"}]}], "classes": [{"title": "Day -28 (n=16,6,3,3,14,15,13,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1160.79", "spread": "1402.74"}, {"groupId": "OG001", "value": "478.99", "spread": "369.31"}, {"groupId": "OG002", "value": "655.76", "spread": "240.78"}, {"groupId": "OG003", "value": "601.40", "spread": "342.13"}, {"groupId": "OG004", "value": "2170.63", "spread": "3899.67"}, {"groupId": "OG005", "value": "1976.98", "spread": "3172.11"}, {"groupId": "OG006", "value": "1775.68", "spread": "2558.08"}, {"groupId": "OG007", "value": "2641.68", "spread": "2332.13"}]}]}, {"title": "Day -1 (n=17,6,3,3,15,17,14,7)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1025.19", "spread": "1287.86"}, {"groupId": "OG001", "value": "296.73", "spread": "185.09"}, {"groupId": "OG002", "value": "589.62", "spread": "175.14"}, {"groupId": "OG003", "value": "522.23", "spread": "259.96"}, {"groupId": "OG004", "value": "2453.85", "spread": "3795.64"}, {"groupId": "OG005", "value": "1655.06", "spread": "2866.87"}, {"groupId": "OG006", "value": "1681.82", "spread": "2161.25"}, {"groupId": "OG007", "value": "2772.55", "spread": "2320.93"}]}]}, {"title": "Day 1 (Predose) (n=17,6,3,3,15,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1155.59", "spread": "1447.09"}, {"groupId": "OG001", "value": "410.78", "spread": "289.39"}, {"groupId": "OG002", "value": "552.30", "spread": "168.96"}, {"groupId": "OG003", "value": "558.69", "spread": "305.68"}, {"groupId": "OG004", "value": "2754.09", "spread": "4468.96"}, {"groupId": "OG005", "value": "1910.45", "spread": "3268.58"}, {"groupId": "OG006", "value": "1850.27", "spread": "2435.13"}, {"groupId": "OG007", "value": "2426.66", "spread": "2460.85"}]}]}, {"title": "Day 1:2 hours postdose (n=0,0,0,0,0,0,0,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG003", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG004", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG005", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG006", "value": "NA", "spread": "NA", "comment": "No participant was evaluable for this outcome measure at this time point."}, {"groupId": "OG007", "value": "0.00", "spread": "0.00"}]}]}, {"title": "Day 2 (n=17,6,3,3,15,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1183.10", "spread": "1494.92"}, {"groupId": "OG001", "value": "71.89", "spread": "157.68"}, {"groupId": "OG002", "value": "302.31", "spread": "195.18"}, {"groupId": "OG003", "value": "336.75", "spread": "294.36"}, {"groupId": "OG004", "value": "1584.76", "spread": "3999.13"}, {"groupId": "OG005", "value": "366.83", "spread": "1499.49"}, {"groupId": "OG006", "value": "94.19", "spread": "351.27"}, {"groupId": "OG007", "value": "0.00", "spread": "0.00"}]}]}, {"title": "Day 3 (n=17,6,3,3,15,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1175.50", "spread": "1550.93"}, {"groupId": "OG001", "value": "74.29", "spread": "168.46"}, {"groupId": "OG002", "value": "282.12", "spread": "179.53"}, {"groupId": "OG003", "value": "293.78", "spread": "259.88"}, {"groupId": "OG004", "value": "1366.58", "spread": "3496.19"}, {"groupId": "OG005", "value": "248.20", "spread": "1022.97"}, {"groupId": "OG006", "value": "42.24", "spread": "157.38"}, {"groupId": "OG007", "value": "0.00", "spread": "0.00"}]}]}, {"title": "Day 5 (n=17,6,3,3,15,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1131.87", "spread": "1448.24"}, {"groupId": "OG001", "value": "74.85", "spread": "169.36"}, {"groupId": "OG002", "value": "297.90", "spread": "193.62"}, {"groupId": "OG003", "value": "277.94", "spread": "240.84"}, {"groupId": "OG004", "value": "1401.33", "spread": "3429.60"}, {"groupId": "OG005", "value": "253.71", "spread": "1045.75"}, {"groupId": "OG006", "value": "0.53", "spread": "1.43"}, {"groupId": "OG007", "value": "0.00", "spread": "0.00"}]}]}, {"title": "Day 8 (n=17,6,3,3,15,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1119.38", "spread": "1417.95"}, {"groupId": "OG001", "value": "85.00", "spread": "192.16"}, {"groupId": "OG002", "value": "366.17", "spread": "239.65"}, {"groupId": "OG003", "value": "288.20", "spread": "250.03"}, {"groupId": "OG004", "value": "1704.44", "spread": "3822.59"}, {"groupId": "OG005", "value": "362.27", "spread": "1408.50"}, {"groupId": "OG006", "value": "3.17", "spread": "10.71"}, {"groupId": "OG007", "value": "0.00", "spread": "0.00"}]}]}, {"title": "Day 15 (n=17,6,3,3,15,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1081.11", "spread": "1338.94"}, {"groupId": "OG001", "value": "74.94", "spread": "161.38"}, {"groupId": "OG002", "value": "418.27", "spread": "193.63"}, {"groupId": "OG003", "value": "362.06", "spread": "246.96"}, {"groupId": "OG004", "value": "2102.53", "spread": "4140.14"}, {"groupId": "OG005", "value": "978.17", "spread": "2490.21"}, {"groupId": "OG006", "value": "209.71", "spread": "539.11"}, {"groupId": "OG007", "value": "0.00", "spread": "0.00"}]}]}, {"title": "Day 22 (n=17,6,3,3,15,17,14,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1084.02", "spread": "1294.17"}, {"groupId": "OG001", "value": "70.95", "spread": "145.36"}, {"groupId": "OG002", "value": "453.89", "spread": "191.07"}, {"groupId": "OG003", "value": "406.12", "spread": "264.19"}, {"groupId": "OG004", "value": "2111.36", "spread": "3730.60"}, {"groupId": "OG005", "value": "1351.52", "spread": "2803.98"}, {"groupId": "OG006", "value": "788.30", "spread": "1783.50"}, {"groupId": "OG007", "value": "0.32", "spread": "0.60"}]}]}, {"title": "Day 29 (n=16,6,3,3,15,17,13,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1185.82", "spread": "1379.20"}, {"groupId": "OG001", "value": "74.02", "spread": "143.04"}, {"groupId": "OG002", "value": "478.53", "spread": "196.36"}, {"groupId": "OG003", "value": "403.17", "spread": "232.44"}, {"groupId": "OG004", "value": "2153.91", "spread": "3376.54"}, {"groupId": "OG005", "value": "1676.12", "spread": "3296.43"}, {"groupId": "OG006", "value": "1468.72", "spread": "3043.16"}, {"groupId": "OG007", "value": "497.42", "spread": "628.41"}]}]}, {"title": "Day 43 (n=16,6,3,3,15,16,13,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1089.90", "spread": "1306.97"}, {"groupId": "OG001", "value": "89.32", "spread": "157.95"}, {"groupId": "OG002", "value": "496.28", "spread": "179.01"}, {"groupId": "OG003", "value": "510.78", "spread": "301.83"}, {"groupId": "OG004", "value": "2712.59", "spread": "4065.37"}, {"groupId": "OG005", "value": "1928.37", "spread": "3371.88"}, {"groupId": "OG006", "value": "1912.71", "spread": "2966.45"}, {"groupId": "OG007", "value": "1674.54", "spread": "1689.61"}]}]}, {"title": "Day 57 (n=16,6,3,3,15,15,12,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1055.20", "spread": "1257.08"}, {"groupId": "OG001", "value": "105.46", "spread": "159.88"}, {"groupId": "OG002", "value": "506.63", "spread": "205.91"}, {"groupId": "OG003", "value": "503.33", "spread": "326.80"}, {"groupId": "OG004", "value": "2201.38", "spread": "3609.05"}, {"groupId": "OG005", "value": "1394.92", "spread": "2394.88"}, {"groupId": "OG006", "value": "2306.44", "spread": "3511.87"}, {"groupId": "OG007", "value": "1978.31", "spread": "1906.57"}]}]}, {"title": "Day 85 (n=15,6,3,3,15,16,12,8)", "categories": [{"measurements": [{"groupId": "OG000", "value": "913.17", "spread": "1142.25"}, {"groupId": "OG001", "value": "294.89", "spread": "377.39"}, {"groupId": "OG002", "value": "526.93", "spread": "227.80"}, {"groupId": "OG003", "value": "530.49", "spread": "292.24"}, {"groupId": "OG004", "value": "2014.95", "spread": "2952.69"}, {"groupId": "OG005", "value": "1749.34", "spread": "2799.68"}, {"groupId": "OG006", "value": "2528.85", "spread": "3967.57"}, {"groupId": "OG007", "value": "2055.68", "spread": "1822.85"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Day 1 to 85", "description": "Safety population included all participants who received any amount of investigational product and had safety data available.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 8, "otherNumAtRisk": 17}, {"id": "EG001", "title": "Omalizumab", "description": "A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 2, "otherNumAtRisk": 6}, {"id": "EG002", "title": "MEDI4212 5 mg Subcutaneous", "description": "A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 2, "otherNumAtRisk": 3}, {"id": "EG003", "title": "MEDI4212 15 mg Subcutaneous", "description": "A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 1, "otherNumAtRisk": 3}, {"id": "EG004", "title": "MEDI4212 60 mg Subcutaneous", "description": "A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 4, "otherNumAtRisk": 15}, {"id": "EG005", "title": "MEDI4212 150 mg Subcutaneous", "description": "A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 9, "otherNumAtRisk": 18}, {"id": "EG006", "title": "MEDI4212 300 mg Subcutaneous", "description": "A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 7, "otherNumAtRisk": 14}, {"id": "EG007", "title": "MEDI4212 300 mg Intravenous", "description": "A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 6, "otherNumAtRisk": 8}], "otherEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Dermoid cyst", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Ear congestion", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Eye irritation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Feeling hot", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Injection site bruising", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Injection site paraesthesia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 8}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 3, "numAffected": 2, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Muscle strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Gamma-glutamyltransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 8}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Nerve compression", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Pulmonary congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Dry skin", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Rash pruritic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 8}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 8}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication."}, "pointOfContact": {"title": "Claire Birrell, Senior Clinical Scientist", "organization": "MedImmune", "email": "birrellc@medimmune.com", "phone": "301-398-0000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000065631", "term": "Rhinitis, Allergic"}, {"id": "D000003876", "term": "Dermatitis, Atopic"}, {"id": "D000003872", "term": "Dermatitis"}, {"id": "D000004485", "term": "Eczema"}], "ancestors": [{"id": "D000012871", "term": "Skin Diseases"}, {"id": "D000012873", "term": "Skin Diseases, Genetic"}, {"id": "D000030342", "term": "Genetic Diseases, Inborn"}, {"id": "D000017443", "term": "Skin Diseases, Eczematous"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "M7071", "name": "Dermatitis, Atopic", "asFound": "Atopic Dermatitis", "relevance": "HIGH"}, {"id": "M7067", "name": "Dermatitis", "asFound": "Dermatitis", "relevance": "HIGH"}, {"id": "M7655", "name": "Eczema", "asFound": "Atopic Dermatitis", "relevance": "HIGH"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M30545", "name": "Rhinitis, Allergic", "asFound": "Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M15674", "name": "Skin Diseases", "relevance": "LOW"}, {"id": "M15676", "name": "Skin Diseases, Genetic", "relevance": "LOW"}, {"id": "M23686", "name": "Genetic Diseases, Inborn", "relevance": "LOW"}, {"id": "M19712", "name": "Skin Diseases, Eczematous", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC17", "name": "Skin and Connective Tissue Diseases"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M19117", "name": "Immunoglobulins, Intravenous", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M10121", "name": "Immunoglobulin E", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}